Jump to content

Drilldown: Medicines

Choose a table:


Medicines > classes : Phenethylamine or [[:Category:P2Y12_inhibitors|P2Y12 receptor inhibitor (reversible)]]

Use the filters below to narrow your results.

generic:
25B-NBOH (1) · 25B-NBOMe (1) · 25C-NBOH (1) · 25C-NBOMe (1) · 25I-NBOH (1) · 25I-NBOMe (1) · 25N-NBOMe (1) · 2C-B (1) · 2C-B-FLY (1) · 2C-C (1) · 2C-D (1) · 2C-E (1) · 2C-I (1) · 2C-P (1) · 2C-T-2 (1) · 2C-T-7 (1) · Allylescaline (1) · Bromo-DragonFLY (1) · DOB (1) · DOC (1) · DOI (1) · DOM (1) · Escaline (1) · Methallylescaline (1) · Proscaline (1) · Ticagrelor (1) · TMA-2 (1)
brand:
None (25) · Brilinta (1) · Nexus, Eroxan (historical, late-1980s through mid-1990s) (1)
classes: (Click arrow to add another value)
mechanism:
None (1) · 5-HT2A agonist (12) · 5-HT2A agonist; long duration (1) · 5-HT2A agonist; MAO inhibitor (1) · 5-HT2A agonist; milder than other 2C-x (1) · 5-HT2A partial agonist (1) · Extremely potent 5-HT2A agonist; vasoconstrictor (1) · Extremely potent 5-HT2A agonist; very long duration (1) · Potent 5-HT2A agonist (5) · Potent 5-HT2A agonist; no oral activity (1) · Potent 5-HT2A agonist; very long duration (1) · Very potent 5-HT2A agonist; long duration (1)
uses:
None (26) · '"`UNIQ--vote-00000C8F-QINU`"', '"`UNIQ--vote-00000C90-QINU`"', '"`UNIQ--vote-00000C91-QINU`"' (1)
starting dose:
None (26) · ACS/PCI: 180 mg PO loading dose, then 90 mg PO BID for 12 months; long-term post-MI: 60 mg BID (1)
preparations:
None (26) · 60, 90 mg tablets (1)
fda max:
None (26) · 90 mg BID (acute year); 60 mg BID (chronic post-MI) (1)
routes:
None (25) · insufflated (1) · Oral (2) · PR (1)
onset:
None (25) · 45-75 min (oral) (1) · Antiplatelet effect within 30 minutes of loading dose (faster than clopidogrel) (1)
duration:
None (25) · 12 hours (1) · 4-8 h (1)
halflife:
None (25) · Not well characterized (1) · ~7 hours (parent); ~9 hours (active AR-C124910XX metabolite, accounts for ~30-40% of activity)'"`UNIQ--ref-00000C92-QINU`"' (1)
bioavailability:
None (25) · Not well characterized (1) · ~36% (oral)'"`UNIQ--ref-00000C93-QINU`"' (1)
pregnancy:
None (25) · Limited data; weigh against alternatives.<sup class="pcp-cn" title="This claim needs a citation.">&#91;[[Pharmacopedia:Citation needed|citation&nbsp;needed]]&#93;</sup> (1) · Not established (1)
legal:
None (25) · [[USLegal:DEA Schedule I|Schedule I]] (United States) (1) · [[USLegal:Prescription only|Rx-only]] in US. Carries a '''Boxed Warning''' for bleeding risk and against aspirin maintenance doses above 100 mg/d (reduces ticagrelor efficacy, per PLATO subgroup analysis)'"`UNIQ--ref-00000C94-QINU`"' (1)

Showing below up to 27 results in range #1 to #27.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"